A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures

This study has been completed.
Sponsor:
Information provided by:
Walter Reed Army Medical Center
ClinicalTrials.gov Identifier:
NCT00413881
First received: December 19, 2006
Last updated: January 13, 2010
Last verified: March 2008
  Purpose

The purpose of this study is to conduct a prospective clinical trial to compare conventional and WFG LASIK for enhancements on post-LASIK patients. Differences in safety, efficacy, visual quality, and refractive stability will also be compared during this study.


Condition Intervention
Refractive Errors
Procedure: WAVEFRONT- GUIDED LASIK ENHANCEMENT
Procedure: CONVENTIONAL LASIK ENHANCEMENT

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures

Resource links provided by NLM:


Further study details as provided by Walter Reed Army Medical Center:

Primary Outcome Measures:
  • 1.Safety 2. Efficacy 3. Refractive stability [ Time Frame: one year after enhancement ]

Estimated Enrollment: 50
Study Start Date: July 2004
Study Completion Date: March 2008
Arms Assigned Interventions
Active Comparator: 2
Conventional LASIK Enhancement
Procedure: CONVENTIONAL LASIK ENHANCEMENT
Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
Experimental: 1
Wavefront guided LASIK Enhancement
Procedure: WAVEFRONT- GUIDED LASIK ENHANCEMENT
Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female, of any race, and at least 21 years old at the time of the preoperative exam, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
  • At least 6 months from original LASIK surgery.
  • Stable refraction with more than 0.75D of spherical equivalent from the desired correction and have less than 1.50D of cylinder in the manifest refraction.
  • Both eyes must be within 1.00D spherical equivalent of each other on the manifest refraction test.
  • The eye to be treated with wavefront-guided enhancement must have at least a 9.5mm flap.
  • Manifest refraction and LADARWave™ refractions must be within 1.00D.
  • At least 3 lines potential improvement in UCVA.
  • BSCVA of 20/20 or better.
  • Good corneal flap and interface.
  • Adequate corneal thickness for surgery (residual stromal bed > 280 microns).
  • Able and willing to give informed consent.
  • Located in the greater Washington DC area for a 12-month period.
  • Access to transportation to meet follow-up requirements.

Exclusion Criteria:

  • Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Pregnancy will be ruled out with a urine pregnancy test.
  • Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin, amiodarone hydrochloride and/ or sumatripin, as determined by history.
  • Medical condition(s), which, in the judgement of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex (As determined by history).
  • Active ophthalmic disease, neovascularization of the cornea within 1mm of the intended ablation zone, or clinically significant lens opacity.
  • Evidence of glaucoma or an intraocular pressure greater than 22mm Hg at baseline.
  • Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye.
  • Flap irregularity(striae, interface debris, scarring, or epithelium).
  • Calculated residual stroma bed less than 280.
  • Stable refraction with less than 0.75D of spherical equivalent from the desired correction and more than 1.5D of cylinder in the manifest refraction.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00413881

Locations
United States, District of Columbia
Walter Reed Army Medical Center, Center For Refractive Surgery
Washington, District of Columbia, United States, 20307
Sponsors and Collaborators
Walter Reed Army Medical Center
Investigators
Principal Investigator: RICHARD STUTZMAN, MD Walter Reed Army Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00413881     History of Changes
Other Study ID Numbers: WRAMC WU # 04-23011
Study First Received: December 19, 2006
Last Updated: January 13, 2010
Health Authority: United States: Federal Government

Keywords provided by Walter Reed Army Medical Center:
Residual refractive error left over from initial LASIK correction.
Higher Order aberrations measured using a wavefront analyzer.

Additional relevant MeSH terms:
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on September 22, 2014